Association of bronchial steroid inducible methylation quantitative trait loci with asthma and chronic obstructive pulmonary disease treatment response

Elise M.A. Slob*, Alen Faiz, Jos van Nijnatten, Susanne J.H. Vijverberg, Cristina Longo, Merve Kutlu, Fook Tim Chew, Yang Yie Sio, Esther Herrera-Luis, Antonio Espuela-Ortiz, Javier Perez-Garcia, Maria Pino-Yanes, Esteban G. Burchard, Uroš Potočnik, Mario Gorenjak, Colin Palmer, Cyrielle Maroteau, Steve Turner, Katia Verhamme, Leila KarimiSomnath Mukhopadhyay, Wim Timens, Pieter S. Hiemstra, Mariëlle W. Pijnenburg, Margaret Neighbors, Michele A. Grimbaldeston, Gaik W. Tew, Corry A. Brandsma, Vojko Berce, Hananeh Aliee, Fabian Theis, Don D. Sin, Xuan Li, Maarten van den Berge, Anke H. Maitland-van der Zee, Gerard H. Koppelman

*Corresponding author for this work

Research output: Contribution to journalComment/Letter to the editorAcademicpeer-review

17 Downloads (Pure)
Original languageEnglish
Article numbere12173
JournalClinical and Translational Allergy
Volume12
Issue number8
DOIs
Publication statusPublished - Aug 2022

Bibliographical note

Funding Information:
The GLUCOLD study (for which these are secondary analyses) was supported by the Netherlands Organisation for Scientific Research (NWO), the Dutch Asthma Foundation, GlaxoSmithKline, the University Medical Center Groningen, and Leiden University Medical Center. Genentech Inc. funded the GLUCOLD bronchial biopsy RNA sequencing project. E.M.A. Slob, S.J.H. Vijverberg, A.H. Maitland‐van der Zee, G.H. Koppelman and M.W. Pijnenburg are conducting the PUFFIN trial that is supported by the Lung Foundation Netherlands, grant number 5.1.16.094. The PACMAN cohort study was funded by a strategic alliance between GlaxoSmithKline and Utrecht Institute for Pharmaceutical Sciences. The SLOVENIA study was financially supported by the Slovenian Research Agency (research core funding No. P3‐0067) and from the SysPharmPedia grant, co‐financed by the Ministry of Education, Science and Sport Slovenia (MIZS) (contract number C3330‐16‐500106). The Genes‐environments and Admixture in Latino Americans (GALA II) Study and the Study of African Americans, Asthma, Genes and Environments (SAGE) were supported in part by the Sandler Family Foundation, the American Asthma Foundation, the RWJF Amos Medical Faculty Development Program, Harry Wm. and Diana V. Hind Distinguished Professor in Pharmaceutical Sciences II, the National Heart, Lung, and Blood Institute of the National Institutes of Health R01HL117004, R01HL128439, R01HL135156, X01HL134589, R01HL141992, R01HL141845, National Institute of Health and Environmental Health Sciences R01ES015794, R21ES24844, the National Institute on Minority Health and Health Disparities P60MD006902, RL5GM118984, R01MD010443, and R56MD013312, the Tobacco‐Related Disease Research Program under Award Number 24RT‐0025, 27IR‐0030 and the National Human Genome Research Institute U01HG009080. The genotyping service of PAGES was carried out at CEGEN‐PRB3‐ISCIII, supported by grant PT17/0019 of the PE I+D+i 2013–2016, funded by ISCIII and ERDF. Maria Pino‐Yanes was funded by the Ramón y Cajal Program by the Spanish Ministry of Science, Innovation, and Universities (MICIU) (RYC‐2015‐17205) and by a grant by MICIU, the State Research Agency, and the European Regional Development Fund from the European Union (MICIU/AEI/FEDER, UE, SAF2017‐83417R). Esther Herera‐Luis was supported by a MICIU fellowship (PRE2018‐083837). Javier Perez‐Garcia was also supported by a Ph.D. fellowship (FPU19/02175) granted by MICIU. Antonio Espuela‐Ortiz was supported by a fellowship granted by MICIU/ULL (M‐ULL). The SLOVENIA study was financially supported by the Slovenian Research Agency (research core funding No. P3‐0067) and from the SysPharmPedia grant, co‐financed by the Ministry of Education, Science and Sport Slovenia (MIZS) (contract number C3330‐16‐500106). F.J. Theis reports receiving consulting fees from Roche Diagnostics GmbH and Cellarity Inc., and ownership interest in Cellarity, Inc. and Dermagnostix.

Funding Information:
The GLUCOLD study (for which these are secondary analyses) was supported by the Netherlands Organisation for Scientific Research (NWO), the Dutch Asthma Foundation, GlaxoSmithKline, the University Medical Center Groningen, and Leiden University Medical Center. Genentech Inc. funded the GLUCOLD bronchial biopsy RNA sequencing project. E.M.A. Slob, S.J.H. Vijverberg, A.H. Maitland-van der Zee, G.H. Koppelman and M.W. Pijnenburg are conducting the PUFFIN trial that is supported by the Lung Foundation Netherlands, grant number 5.1.16.094. The PACMAN cohort study was funded by a strategic alliance between GlaxoSmithKline and Utrecht Institute for Pharmaceutical Sciences. The SLOVENIA study was financially supported by the Slovenian Research Agency (research core funding No. P3-0067) and from the SysPharmPedia grant, co-financed by the Ministry of Education, Science and Sport Slovenia (MIZS) (contract number C3330-16-500106). The Genes-environments and Admixture in Latino Americans (GALA II) Study and the Study of African Americans, Asthma, Genes and Environments (SAGE) were supported in part by the Sandler Family Foundation, the American Asthma Foundation, the RWJF Amos Medical Faculty Development Program, Harry Wm. and Diana V. Hind Distinguished Professor in Pharmaceutical Sciences II, the National Heart, Lung, and Blood Institute of the National Institutes of Health R01HL117004, R01HL128439, R01HL135156, X01HL134589, R01HL141992, R01HL141845, National Institute of Health and Environmental Health Sciences R01ES015794, R21ES24844, the National Institute on Minority Health and Health Disparities P60MD006902, RL5GM118984, R01MD010443, and R56MD013312, the Tobacco-Related Disease Research Program under Award Number 24RT-0025, 27IR-0030 and the National Human Genome Research Institute U01HG009080. The genotyping service of PAGES was carried out at CEGEN-PRB3-ISCIII, supported by grant PT17/0019 of the PE I+D+i 2013–2016, funded by ISCIII and ERDF. Maria Pino-Yanes was funded by the Ramón y Cajal Program by the Spanish Ministry of Science, Innovation, and Universities (MICIU) (RYC-2015-17205) and by a grant by MICIU, the State Research Agency, and the European Regional Development Fund from the European Union (MICIU/AEI/FEDER, UE, SAF2017-83417R). Esther Herera-Luis was supported by a MICIU fellowship (PRE2018-083837). Javier Perez-Garcia was also supported by a Ph.D. fellowship (FPU19/02175) granted by MICIU. Antonio Espuela-Ortiz was supported by a fellowship granted by MICIU/ULL (M-ULL). The SLOVENIA study was financially supported by the Slovenian Research Agency (research core funding No. P3-0067) and from the SysPharmPedia grant, co-financed by the Ministry of Education, Science and Sport Slovenia (MIZS) (contract number C3330-16-500106). F.J. Theis reports receiving consulting fees from Roche Diagnostics GmbH and Cellarity Inc., and ownership interest in Cellarity, Inc. and Dermagnostix.

Cite this